Sector News

Those PBM moves pharma loves to hate? They work, CVS says–so get used to them

February 23, 2016
Life sciences

Drugmakers may not be too keen on the formulary management techniques and exclusive deals pharmacy benefits managers have been using to combat rising drug prices. But new numbers from a PBM giant suggest they work–and that pharma better get used to them.

Tuesday, CVS Health announced that its prescription drug trend–a metric for growth in prescription spending–had dropped to 5% in 2015, down from an all-time high of 11.8% in 2014. And with many of the usual drivers staying consistent over both periods–including brands and price inflation among generic and specialty drugs—the company is chalking up the drop as proof its tactics are doing their job.

CVS’ “proactive pharmacy management strategies were successful in mitigating the impact of rising drug costs in today’s highly volatile prescription drug market,” it said in a statement, with Chief Medical Officer Troyen Brennan noting that, “[W]e work to help patients avoid unnecessarily expensive medications as part of our focus on making prescriptions affordable.”

CVS and its main rival, Express Scripts, have both been actively pruning their preferred formularies over the past few years, with CVS getting the party started back in 2011. At that time, it gave 34 meds the boot as part of a pilot program; by the time it announced its exclusions for 2015, its list tallied nearly 100 drugs and related products, with Express Scripts chipping in with 66 of its own.

Between 2014 and 2015, CVS bade farewell to AstraZeneca diabetes meds Farxiga and Byetta, fast-acting Sanofi insulin Apridra, Merck KGaA multiple sclerosis therapy Rebif and sleep aid Lunesta, among others. And the company has shown no signs of slowing down: Monday, Bloomberg reported that it was planning to restrict the use of Valeant toenail fungus treatment Jublia as part of dermatology cost-cutting initiative.

CVS has also struck exclusive deals in hep C and cholesterol, a couple hot therapy areas with high-priced hot-shot newcomers. Early last year, after Express Scripts touched off a pricing war by barring Gilead’s hep C meds, the California biotech struck back with a CVS exclusive that knocked out a therapy from nemesis AbbVie. More recently, CVS sided with Amgen in a battle between two new PCSK9 contenders.

Unsurprisingly, pharma hasn’t taken too kindly to the moves, but some companies have been more accepting of the current climate than others. GlaxoSmithKline and Novartis, to name a couple, have been working to avoid payers’ wrath, with Glaxo moving its attention instead to low-priced OTC products and vaccines and Novartis trailblazing with pay-for-performance deals.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach